Ancillare
Ancillare is recorded as a service provider in 44 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 44 trials · Latest update first
Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP 101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
Sponsor Heidelberg Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, First-in-Human Study of theMenin-KMT2A (MLL1)Inhibitor Bleximenib in Participants with Acute Leukemia
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-label, Randomized Study to Evaluate GPRC5D-related Oral Events
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myopathies
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma CARTITUDE-2
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Subjects with Active Psoriatic Arthritis Axial Disease
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (≥6 To <18 Years of Age)
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma CARTITUDE-4
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Ancillare?
The 2026-10-09 snapshot links Ancillare to 44 distinct CTIS trials. Recorded services include Ancillary Supplies, Ancillary supplies, Ancillary supply provider, IP Supplies, among 29 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ancillare?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology, Dermatology, Gastroenterology. Recorded phases include Phase 2, Phase 3, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ancillare conducted?
The linked trials record locations in 22 countries, including Spain, Germany, France, Poland, Italy. These are trial locations, not confirmed office locations or countries where Ancillare delivered services.
What can this page tell me about Ancillare's trial experience?
Browse 44 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Ancillare. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ancillare LP